Psoriasis and melanocytic naevi: Does the first confer a protective role against melanocyte progression to naevi?

British Journal of Dermatology

Volumn 164, Issue 6, 2011, Pages 1262-1270

  Balato, N ^a   Di Costanzo, L ^a   Balato, A ^a   Patruno, C ^a   Scalvenzi, M ^a   Ayala, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1ALPHA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FAMILY HISTORY; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MELANOCYTE; MELANOCYTIC NEVUS; MELANOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEVUS, PIGMENTED; PEDIGREE; PHENOTYPE; PROSPECTIVE STUDIES; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79957585973     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10271.x     Document Type: Article

References (39)

1. Lebwohl M,. Psoriasis. Lancet 2003; 361: 1197-204. (Pubitemid 36398393)
2. Krueger JG,. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23. (Pubitemid 34073472)
3. Nickoloff BJ, Nestle FO,. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113: 1664-75. (Pubitemid 39071656)
4. Bowcock AM, Krueger JG,. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 2005; 5: 699-711. (Pubitemid 43090738)
5. Schon MP, Boehncke WH,. Psoriasis. N Engl J Med 2005; 352: 1899-912. (Pubitemid 40627816)
6. Gaspari AA,. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006; 54: S67-80. (Pubitemid 43243477)
7. Lowes MA, Bowcock AM, Krueger JG,. Pathogenesis and therapy of psoriasis. Nature 2007; 445: 866-73.
8. Albanesi C, De Pità O, Girolomoni G,. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol 2007; 25: 581-8. (Pubitemid 350087605)
9. Bos JD, de Rie MA, Teunissen MBM, et al. Psoriasis: dysregulation of innate immunity. Br J Dermatol 2005; 152: 1098-107. (Pubitemid 40933406)
10. Finch PW, Murphy F, Cardinale I, et al. Altered expression of keratinocyte growth factor and its receptor in psoriasis. Am J Pathol 1997; 151: 1619-28. (Pubitemid 27527924)
11. Swope VB, Abdel-Malek Z, Kassem LM, et al. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991; 96: 180-5.
12. Park HY, Kosmadaki M, Yaar M, et al. Cellular mechanisms regulating human melanogenesis. Cell Mol Life Sci 2009; 66: 1493-506.
13. Thanigaimalai P, Lee KC, Bang SC, et al. Inhibitory effect of novel tetrahydropyrimidine-2(1H)-thiones on melanogenesis. Bioorg Med Chem 2010; 18: 1135-42.
14. Cardinali G, Ceccarelli S, Kovacs D, et al. Keratinocyte growth factor promotes melanosome transfer to keratinocytes. J Invest Dermatol 2005; 125: 1190-9.
15. Wintzen M, Yaar M, Aila E, et al. Keratinocytes produce beta-endorphin and betalipotropic hormone after stimulation by UV, IL-1α or phorbol esters. J Invest Dermatol 1995; 104: 641-8.
16. Imokawa G, Yada Y, Miyagishi M,. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem 1992; 267: 24675-80.
17. Tomita Y, Maeda K, Tagami H,. Mechanisms for hyperpigmentation in postinflammatory pigmentation, urticaria pigmentosa and sunburn. Dermatologica 1989; 179: 49-53. (Pubitemid 19174931)
18. Halaban R, Langdon R, Birchall N, et al. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol 1988; 107: 1611-19.
19. Martínez-Esparza M, Jiménez-Cervantes C, Solano F, et al. Mechanisms of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells. Eur J Biochem 1998; 255: 139-46. (Pubitemid 28316846)
20. Woodhouse J, Maytin EV,. Eruptive nevi of the palms and soles. J Am Acad Dermatol 2005; 52: S96-100.
21. Bovenschen HJ, Tjioe M, Vermaat H, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol 2006; 154: 880-4.
22. Kelley BP, Doherty SD, Calame A, et al. Acquired dermal melanocytosis of the hand at the site of treated psoriasis. Dermatol Online J 2009; 15: 2.
23. Richert S, Bloom EJ, Flynn K, et al. Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. J Am Acad Dermatol 1996; 35: 326-9. (Pubitemid 26257270)
24. Fitzpatrick TB,. Soleil et peau. J Med Esthet 1975; 2: 33-4.
25. Changchien L, Dusza SW, Agero AL, et al. Age- and site-specific variation in the dermoscopic patterns of congenital melanocytic nevi: an aid to accurate classification and assessment of melanocytic nevi. Arch Dermatol 2007; 143: 1007-14. (Pubitemid 47296077)
26. Johr RH,. Dermoscopy: alternative melanocytic algorithms-the ABCD rule of dermatoscopy, Menzies scoring method, and 7-point checklist. Clin Dermatol 2002; 20: 240-7. (Pubitemid 34628890)
27. Broberg A, Augustsson A,. Atopic dermatitis and melanocytic naevi. Br J Dermatol 2000; 142: 306-9. (Pubitemid 30117702)
28. Synnerstad I, Nilsson L, Fredrikson M, et al. Fewer melanocytic nevi found in children with active atopic dermatitis than in children without dermatitis. Arch Dermatol 2004; 140: 1471-5. (Pubitemid 39627438)
29. Kallas M, Rosdahl I, Fredriksson M, et al. Frequency and distribution pattern of melanocytic naevi in Estonian children and the influence of atopic dermatitis. J Eur Acad Dermatol Venereol 2006; 20: 143-8. (Pubitemid 43740512)
30. Synnerstad I, Fredrikson M, Ternesten-Bratel A, et al. Low risk of melanoma in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2008; 22: 1423-8.
31. Simõn JA, Burgos-Vargas R,. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology 2008; 216: 234-5. (Pubitemid 351416724)
32. Lv Y, Li Q, Wang L, Gao T,. Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo. Med Hypotheses 2009; 72: 546-7.
33. Moretti S, Spallanzani A, Amato L, et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002; 15: 87-92. (Pubitemid 34536320)
34. Ahmed AA, Nordlind K, Hedblad M, et al. Interleukin (IL)-1 alpha- and -1 beta-, IL-6-, and tumor necrosis factor-alpha-like immunoreactivities in human common and dysplastic nevocellular nevi and malignant melanoma. Am J Dermatopathol 1995; 17: 222-9.
35. Rabin RL, Levinson AI,. The nexus between atopic disease and autoimmunity: a review of the epidemiological and mechanistic literature. Clin Exp Immunol 2008; 153: 19-30. (Pubitemid 351809345)
36. Paltiel O, Adler B, Herschko K, et al. Are patients with psoriasis susceptible to the classic risk factors for actinic keratoses? Arch Dermatol 2004; 140: 805-10. (Pubitemid 38917848)
37. Møller P, Wallin H, Dybdahl M, et al. Psoriasis patients with basal cell carcinoma have more repair-mediated DNA strand-breaks after UVC damage in lymphocytes than psoriasis patients without basal cell carcinoma. Cancer Lett 2000; 151: 187-92. (Pubitemid 30156793)
38. Dybdahl M, Frentz G, Vogel U, et al. Low DNA repair is a risk factor in skin carcinogenesis: a study of basal cell carcinoma in psoriasis patients. Mutat Res 1999; 433: 15-22. (Pubitemid 29073666)
39. Nickoloff BJ,. Creation of psoriatic plaques: the ultimate tumor suppressor pathway. J Cutan Pathol 2001; 28: 57-64.